The Danish Group stated that the new corporate culture – dubbed 'The Novo Way' – centres around four Cs; namely, customer ...

GSK reported good clinical trial results with two of its lung cancer therapies – Jideytro and risvutatug rezetecan (ris-rez) ...

The offer is legally conditioned upon the private equity company's Respighi BidCo vehicle securing at least a two-thirds ...

Etcamah is already approved in the US, Europe, and other markets for use in combination with a CDK4/6 inhibitor as a ...

Jiangsu Hengrui Pharma's oral thrombopoietin (TPO) receptor agonist hetrombopag has been approved in China to treat low ...

Right after reporting encouraging data with its Dravet syndrome gene therapy, Encoded Therapeutics has raised an impressive ...

PMV Pharma is preparing to file for approval of its oral p53 protein reactivator drug rezatopopt in the first quarter of 2027 ...

Hard on the heels of a big disappointment in its cardiovascular pipeline, Novartis has suffered another – this time for its ...

The milestones in xenotransplantation – cross-species transplants – rely on cutting-edge biotechnologies, including the use ...

Amgen's fast-growing cancer immunotherapy Imdelltra could move into the first-line setting in small cell lung cancer (SCLC), ...

The pivotal QUINTESSENTIAL trial of the potentially first-in-class CAR-T showed a "statistically significant and clinically ...

Novo Nordisk has opted to discontinue two late-stage trials of IL-6 inhibitor ziltivekimab in heart failure, after an interim ...